Concepedia

Lucy Gong

LG

Statistics

Publications

13

Citations

788

H-Index

12

Active since

2008

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

UPMC Hillman Cancer Center

City Of Hope National Medical Center

Huntsman Cancer Institute

University of Utah

Lucy Gong is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and cancer immunotherapy.

Publications per year

2008–2021

13

Publications

13

A Binding Domain on Mesothelin for CA125/MUC16

Osamu Kaneko, Lucy Gong, Jingli Zhang et al. · Journal of Biological Chemistry · 2008 · 221 citations · Full text

, , +12

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

Anas Younes, Jesús G. Berdeja, Manish R. Patel et al. · The Lancet Oncology · 2016 · 187 citations

, , +15

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie et al. · Blood · 2021 · 120 citations · Full text

, , +17

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, Kathleen Dorritie, Javier Muñoz et al. · Blood · 2020 · 53 citations

, , +17

Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.

James J. Lee, John D. Powderly, Manish R. Patel et al. · Journal of Clinical Oncology · 2017 · 45 citations

, , +17

1–5 of 13